Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Cell|August 6, 2013
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progressionChia-Hsin Chan, John Kenneth Morrow, Chien-Feng Li, et al.
Fundamental Research|October 21, 2024
Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancerJing Ni, Mengyun Wang, Tianpei Wang, et al.
Nature Communications|March 31, 2015
Skp2-macroH2A1-CDK8 axis orchestrates G2/M transition and tumorigenesisDazhi Xu, Chien-Feng Li, Xian Zhang, et al.
The Journal of Pathology|June 5, 2023
The E2F1-HOXB9/PBX2-CDK6 axis drives gastric tumorigenesis and serves as a therapeutic target in gastric cancerJinglin Zhang, Bonan Chen, Yifei Wang, et al.
Cancer Research|July 24, 2024
FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives MetastasisXiaoli Liu, Bonan Chen, Fuda Xie, et al.
Molecular Cancer|July 3, 2025
STK3 is a transcriptional target of YAP1 and a hub component in the crosstalk between Hippo and Wnt signaling pathways during gastric carcinogenesisFuda Xie, Yang Lyu, Bonan Chen, et al.
Gut|August 7, 2019
Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populationsCaiwang Yan, Meng Zhu, Yanbing Ding, et al.
The Lancet. Oncology|October 1, 2020
Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort studyGuangfu Jin, Jun Lv, Ming Yang, et al.
Clinical and Translational Medicine|November 20, 2023
H. pylori-induced NF-κB-PIEZO1-YAP1-CTGF axis drives gastric cancer progression and cancer-associated fibroblast-mediated tumour microenvironment remodellingBonan Chen, Xiaoli Liu, Peiyao Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)Chen Li, Yantao Tian, Yanan Zheng, et al.
Pageof 8